2. Search Result
Search Result
Results for "

fibrinolytic

" in MedChemExpress (MCE) Product Catalog:

31

Inhibitors & Agonists

1

Fluorescent Dyes

4

Biochemical Assay Reagents

2

Peptides

10

Natural
Products

4

Isotope-Labeled Compounds

4

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P2373
    Kinase, Natto fermentation
    4 Publications Verification

    		 PAI-1 Cardiovascular Disease
    Kinase, Natto fermentation is a potent fibrinolytic enzyme. Kinase, Natto fermentation can break down blood clots by directly hydrolyzing fibrin and plasmin substrate. Kinase, Natto fermentation can be used for the research of cardiovascular diseases .
    Kinase, Natto fermentation
  • HY-B0715
    Pentoxifylline
    10+ Cited Publications

    BL-191; PTX; Oxpentifylline

    		 Phosphodiesterase (PDE) Autophagy HIV Cardiovascular Disease Cancer
    Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation .
    Pentoxifylline
  • HY-17566
    Capreomycin sulfate
    5 Publications Verification

    		 Antibiotic Bacterial Infection Neurological Disease Metabolic Disease
    Capreomycin sulfate is a macrocyclic peptide antibiotic that inhibits phenylalanine synthesis in mycobacterial ribosomal translation. Capreomycin sulfate has anti-amyloidogenic and pro-fibrinolytic activities, reducing amyloid-induced cytotoxicity by inhibiting the occurrence of amyloid fibrillation. Capreomycin sulfate can be used in the study of multidrug-resistant tuberculosis, type 2 diabetes, Alzheimer's disease and Parkinson's disease .
    Capreomycin sulfate
  • HY-P2970
    Stem bromelain

    		Apoptosis PARP Caspase Bcl-2 Family Bacterial Interleukin Related Infection Inflammation/Immunology Cancer
    Stem bromelain (EC 3.4.22.32) is a cysteine protease and antibacterial agent. Stem bromelain can be isolated from the stem of the pineapple (Ananas comosus). Stem bromelain induces dose-dependent secretion of IL-12p70, and IL-6, induces Apoptosis, causes cleavage of full-length PARP protein, Caspase 3, and Caspase 9, increases Bax, and decreases Bcl-2. Stem bromelain possesses various fibrinolytic, antiedema, antithrombotic, and anti-inflammatory activities. Stem bromelain also exhibits in vivo antitumor and antileukemic activities, as well as antimetastatic effects. Stem bromelain has antimycobacterial activity. Stem bromelain provides protection against lead poisoning .
    Stem bromelain
  • HY-129611
    Bromelain

    		Apoptosis Inflammation/Immunology Cancer
    Bromelain is an anti-inflammatory agent derived from pineapple stem that acts through down-regulation of plasma kininogen, inhibition of Prostaglandin E2 expression, degradation of advanced glycation end product receptors and regulation of angiogenic biomarkers as well as antioxidant action upstream in the COX-pathway . Bromelain exhibits various fibrinolytic, antiedematous, antithrombotic, and anti-inflammatory activities. Bromelain also possesses some anticancerous activities and promotes apoptotic cell death .
    Bromelain
  • HY-131409
    D-Val-Leu-Lys-pNA dihydrochloride

    D-Val-Leu-Lys-p-itoailide dihydrochloride; D-VLK-pNA dihydrochloride; S 2251 dihydrochloride

    		 Fluorescent Dye Others
    D-Val-Leu-Lys-pNA (D-Val-Leu-Lys-p-nitroanilide) dihydrochloride is a chromogenic peptide substrate that serves as a characteristic substrate for plasmin and plasminogen. D-Val-Leu-Lys-pNA dihydrochloride acts as a sensitive substrate for the DFE27 serine protease derived from Bacillus subtilis DC27. Catalyzed by plasmin, D-Val-Leu-Lys-pNA dihydrochloride binds and hydrolyzes to release p-nitroaniline (pNA), which can be detected colorimetrically at 405 nm as a measure of fibrinolytic activity .
    D-Val-Leu-Lys-pNA dihydrochloride
  • HY-B1399
    3-Methylsalicylic acid

    o-Cresotic acid; Hydroxytoluic acid

    		 Endogenous Metabolite Cardiovascular Disease
    3-Methylsalicylic acid (o-Cresotic acid) is a derivative of salicylic acid. 3-Methylsalicylic acid exhibits significant fibrinolytic activity in human plasma by activating the fibrinolytic system. 3-Methylsalicylic acid can be used as an intermediate for the synthesis of other compounds. 3-Methylsalicylic acid inhibits the feeding of midges .
    3-Methylsalicylic acid
  • HY-155909A
    m-PEG1000-NHS ester

    mPEG1000-SC; mPEG1000-Succinimidyl ester

    		 Biochemical Assay Reagents Others
    m-PEG1000-NHS ester can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.
    m-PEG1000-NHS ester
  • HY-155909C
    m-PEG350-NHS ester

    mPEG350-SC; mPEG350-Succinimidyl ester

    		 Biochemical Assay Reagents Others
    m-PEG350-NHS ester can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.
    m-PEG350-NHS ester
  • HY-122052
    UK‑396082

    		Thrombin Metabolic Disease
    UK‑396082 is a potent thrombin activated fibrinolytic inhibitor (TAFI) inhibitor. UK‑396082 increases plasmin activity and induces a parallel decrease in ECM levels. UK‑396082 can be used in research of chronic kidney disease (CKD) .
    UK‑396082
  • HY-B0715S2
    Pentoxifylline-d5

    BL-191-d5; PTX-d5; Oxpentifylline-d5

    		 Phosphodiesterase (PDE) Autophagy HIV Cardiovascular Disease Cancer
    Pentoxifylline-d5 is the deuterium labeled Pentoxifylline. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation .
    Pentoxifylline-d5
  • HY-155909
    m-PEG3400-NHS ester

    mPEG3400-SC; mPEG3400-Succinimidyl ester

    		 Biochemical Assay Reagents Others
    m-PEG3400-NHS ester can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.
    m-PEG3400-NHS ester
  • HY-155909B
    m-PEG550-NHS ester

    mPEG550-SC; mPEG550-Succinimidyl ester

    		 Biochemical Assay Reagents Others
    m-PEG550-NHS ester can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.
    m-PEG550-NHS ester
  • HY-B0715S
    Pentoxifylline-d6

    BL-191-d6; PTX-d6; Oxpentifylline-d6

    		 Phosphodiesterase (PDE) Autophagy HIV Cardiovascular Disease Cancer
    Pentoxifylline-d6 is the deuterium labeled Pentoxifylline. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation .
    Pentoxifylline-d6
  • HY-B0715R
    Pentoxifylline (Standard)

    BL-191 (Standard); PTX (Standard); Oxpentifylline (Standard)

    		 HIV Autophagy Phosphodiesterase (PDE) Reference Standards Cardiovascular Disease Cancer
    Pentoxifylline (Standard) is the analytical standard of Pentoxifylline. This product is intended for research and analytical applications. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation .
    Pentoxifylline (Standard)
  • HY-N14452
    Plactin A

    		Others Others
    Plactin A is a cyclic pentapeptide physiologically active substance and promotes the dissolution of fibrinolytic proteins .
    Plactin A
  • HY-N14455
    Plactin D

    		Others Others
    Plactin D is a cyclic pentapeptide physiologically active substance and promotes the dissolution of fibrinolytic proteins .
    Plactin D
  • HY-B1399R
    3-Methylsalicylic acid (Standard)

    o-Cresotic acid (Standard); Hydroxytoluic acid (Standard)

    		 Endogenous Metabolite Reference Standards Cardiovascular Disease
    3-Methylsalicylic acid (Standard) is the analytical standard of 3-Methylsalicylic acid. This product is intended for research and analytical applications. 3-Methylsalicylic acid (o-Cresotic acid) is a derivative of salicylic acid. 3-Methylsalicylic acid exhibits significant fibrinolytic activity in human plasma by activating the fibrinolytic system. 3-Methylsalicylic acid can be used as an intermediate for the synthesis of other compounds. 3-Methylsalicylic acid inhibits the feeding of midges.
    3-Methylsalicylic acid (Standard)
  • HY-172536
    m-PEG30000-NHS ester

    mPEG30000-SC; mPEG30000-Succinimidyl ester

    		 Biochemical Assay Reagents Others
    m-PEG30000-NHS ester (mPEG30000-SC) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects .
    m-PEG30000-NHS ester
  • HY-W743984
    Melagatran-d11

    		Isotope-Labeled Compounds Thrombin Cardiovascular Disease
    Melagatran-d11 is the deuterium labeled Melagatran (HY-129056). Melagatran is a direct and orally active inhibitor of thrombin, without interacting with any other enzymes in the coagulation cascade or fibrinolytic enzymes aside from thrombin. Melagatran does not require endogenous co-factors for its antithrombin effect and may help to alleviate some of the damaging effects of endotoxemia . Melagatran has the potential to provide a rational approach in the prevention of arterial occlusion .
    Melagatran-d11
  • HY-168378
    D-Val-Leu-Lys-pNA

    S-2251

    		 Fluorescent Dye Others
    D-Val-Leu-Lys-pNA (S-2251) is a chromogenic peptide substrate that serves as a characteristic substrate for plasmin and plasminogen. D-Val-Leu-Lys-pNA acts as a sensitive substrate for the DFE27 serine protease derived from Bacillus subtilis DC27. Catalyzed by plasmin, D-Val-Leu-Lys-pNA binds and hydrolyzes to release p-nitroaniline (pNA), which can be detected colorimetrically at 405 nm as a measure of fibrinolytic activity .
    D-Val-Leu-Lys-pNA
  • HY-B0715S3
    Pentoxifylline-d3

    BL-191-d3; PTX-d3; Oxpentifylline-d3

    		 Isotope-Labeled Compounds Autophagy Phosphodiesterase (PDE) HIV Cardiovascular Disease Cancer
    Pentoxifylline-d3 (BL-191-d3) is deuterium labeled Pentoxifylline. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation .
    Pentoxifylline-d3
  • HY-113769
    WB 3559 A

    		PAI-1 Cardiovascular Disease
    WB 3559 A is a fibrinolytic plasminogen activator. WB 3559 A accelerates the conversion of plasminogen to plasmin and directly degrades fibrin in thrombi. WB 3559 A is promising for research of acute thrombotic diseases (e.g., myocardial infarction, pulmonary embolism) .
    WB 3559 A
  • HY-N14454
    Plactin C

    		Others Others
    Plactin C is a cyclic pentapeptide physiologically active substance and promotes the dissolution of fibrinolytic proteins .
    Plactin C
  • HY-N14453
    Plactin B

    		Others Others
    Plactin B is a cyclic pentapeptide physiologically active substance and promotes the dissolution of fibrinolytic proteins .
    Plactin B
  • HY-N14448
    11-Keto-9(E),12(E)-octadecadienoic acid

    		Others Cardiovascular Disease
    11-Keto-9(E),12(E)-octadecadienoic acid has enhanced endothelial cell fibrinolytic activity .
    11-Keto-9(E),12(E)-octadecadienoic acid
  • HY-114150B
    D-Val-Leu-Arg-pNA hydrochloride

    		PAI-1 Others
    D-Val-Leu-Arg-pNA hydrochloride is a substrate for glandular kinin-releasing enzymes. D-Val-Leu-Arg-pNA hydrochloride can be used to determine the activities of plasminogen activator and plasmin. D-Val-Leu-Arg-pNA hydrochloride is also used to study the fibrinolytic activity of various organisms, such as bacteria and worms .
    D-Val-Leu-Arg-pNA hydrochloride
  • HY-P2824A
    Streptokinase, Streptococcus hemolyticus

    		Endogenous Metabolite Metabolic Disease
    Streptokinase, Streptococcus hemolyticus (EC 3.4.99.0) is an enzyme secreted by several species of streptococci that can bind and activate human plasminogen. Streptokinase belongs to a group of medications known as fibrinolytics, and complexes of streptokinase with human plasminogen can hydrolytically activate other unbound plasminogen by activating through bond cleavage to produce plasmin.
    Streptokinase, Streptococcus hemolyticus
  • HY-105363
    RGH-1962

    		Others Cardiovascular Disease
    RGH-1962 is an orally active antithrombotic agent. RGH-1962 prevents endotoxin-induced decreases in fibrinogen level and platelet count, reduces the level of fibrin degradation products and inhibits the endotoxin-induced enhancement of fibrinolytic activity in a rabbit model of endotoxin-induced disseminated intravascular coagulation. RGH-1962 can be used for the study of thrombotic diseases .
    RGH-1962
  • HY-105364
    RGH-1875 hydriodide

    GYKI 39521 hydriodide

    		 Others Cardiovascular Disease
    RGH-1875 (GYKI 39521) hydriodide is the hydriodide of RGH-1875. RGH-1875 is an orally active antithrombotic agent. RGH-1875 prevents endotoxin-induced decreases in fibrinogen level and platelet count, reduces the level of fibrin degradation products and inhibits the endotoxin-induced enhancement of fibrinolytic activity in a rabbit model of endotoxin-induced disseminated intravascular coagulation. RGH-1875 can be used for the study of thrombotic diseases .
    RGH-1875 hydriodide
  • HY-168378A
    D-Val-Leu-Lys-pNA acetate

    S-2251 acetate

    		 Fluorescent Dye Others
    D-Val-Leu-Lys-pNA acetate (S-2251 acetate) is a chromogenic peptide substrate that serves as a characteristic substrate for plasmin and plasminogen. D-Val-Leu-Lys-pNA acetate acts as a sensitive substrate for the DFE27 serine protease derived from Bacillus subtilis DC27. Catalyzed by plasmin, D-Val-Leu-Lys-pNA acetate binds and hydrolyzes to release p-nitroaniline (pNA), which can be detected colorimetrically at 405 nm as a measure of fibrinolytic activity .
    D-Val-Leu-Lys-pNA acetate

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: